Baillie Gifford Bolsters Stake in Nanobiotix SA
In This Article:
Baillie Gifford (Trades, Portfolio), the renowned investment management firm, has recently increased its investment in Nanobiotix SA, a company at the forefront of nanotechnology in cancer treatment. On December 1, 2023, Baillie Gifford (Trades, Portfolio) added 932,835 shares to its position, bringing the total number of shares held to 2,869,030. This transaction was executed at a trade price of $5.81 per share, reflecting a 48.18% change in the firm's holdings and a 6.21% ownership in Nanobiotix SA. Despite the significant addition, the trade had a negligible impact on Baillie Gifford (Trades, Portfolio)'s portfolio, with the position accounting for just 0.02% of its total investments.
Investment Management with a Century of Expertise
Baillie Gifford (Trades, Portfolio)'s legacy spans over a century, with a focus on prioritizing existing clients' interests and maintaining the integrity of its investment strategies. The firm manages assets for some of the world's largest professional investors, including pension funds and financial institutions across various continents. Baillie Gifford (Trades, Portfolio)'s investment philosophy is rooted in a long-term, bottom-up approach, emphasizing fundamental analysis and proprietary research to identify companies with sustainable growth potential. The firm's top holdings include prominent names such as Amazon.com Inc (NASDAQ:AMZN), MercadoLibre Inc (NASDAQ:MELI), and NVIDIA Corp (NASDAQ:NVDA), with a significant equity of $126.19 billion predominantly invested in the Technology and Consumer Cyclical sectors.
Nanobiotix SA: Pioneering Nanotechnology in Cancer Treatment
Nanobiotix SA, listed under the stock symbol NBTX and headquartered in France, made its public debut on December 11, 2020. The company is dedicated to revolutionizing cancer treatment by enhancing the efficacy of radiotherapy. Its flagship product candidate, NBTXR3, is designed to amplify the impact of radiotherapy on tumor cells while sparing healthy tissues. Nanobiotix operates primarily in the biotechnology industry, with a market capitalization of $385.36 million.
Market Performance and Valuation of Nanobiotix SA
Since its IPO, Nanobiotix SA's stock price has experienced a decline of 56.12%, but it has shown signs of recovery with a year-to-date increase of 11.37% and a significant gain of 40.79% since Baillie Gifford (Trades, Portfolio)'s trade date. Despite the recent uptick, the stock is currently labeled as a "Possible Value Trap" by GuruFocus, urging investors to think twice before investing. The GF Value of the stock stands at $4,267.07, but with a current stock price of $8.18, the price to GF Value ratio is not applicable, indicating that the company may not be undervalued. The GF Score of Nanobiotix SA is 48/100, suggesting poor future performance potential.